Literature DB >> 1454372

Effects of monochromatic and chromatic oblique aberrations on visual performance during spectacle lens wear.

C Y Tang1, W N Charman.   

Abstract

An optical system is described which allows overall visual performance to be studied when the wearer of a spectacle lens views objects through the lens periphery. Performance with lenses of any refractive power can be explored without any need for subjects to have the appropriate complementary refractive errors. In comparison with the effects of dioptric defocus, transverse chromatic aberration (TCA) is found to cause a relatively greater degradation in contrast sensitivity at high spatial frequencies when tangentially-oriented gratings are observed. The relative importance of TCA appears to have been underestimated in some previous studies. As vision is found to be affected by both TCA and defocus, a careful compromise between chromatic and monochromatic aberrations is required.

Entities:  

Mesh:

Year:  1992        PMID: 1454372

Source DB:  PubMed          Journal:  Ophthalmic Physiol Opt        ISSN: 0275-5408            Impact factor:   3.117


  3 in total

1.  [The aspheric blue light filter IOL AcrySof IQ compared to the AcrySof SA60AT : influence of IOL power, pupil diameter, and corneal asphericity on postoperative spherical aberration].

Authors:  U Mester; H Kaymak
Journal:  Ophthalmologe       Date:  2008-11       Impact factor: 1.059

2.  Effects of chalazia on corneal astigmatism : Large-sized chalazia in middle upper eyelids compress the cornea and induce the corneal astigmatism.

Authors:  Ki Won Jin; Young Joo Shin; Joon Young Hyon
Journal:  BMC Ophthalmol       Date:  2017-03-31       Impact factor: 2.209

3.  Refractive, visual, and subjective quality of vision outcomes for very high myopia LASIK from - 10.00 to - 13.50 diopters.

Authors:  Avi Wallerstein; Joseph Wai Keung Kam; Mathieu Gauvin; Eser Adiguzel; Mounir Bashour; Ananda Kalevar; Mark Cohen
Journal:  BMC Ophthalmol       Date:  2020-06-17       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.